A prescribed walking regimen plus arginine supplementation improves function and quality of life for patients with pulmonary arterial hypertension: A pilot study

Mary Beth Brown, Attie Kempf, Catherine M. Collins, Gary M. Long, Matthew Owens, Shikha Gupta, Yaron Hellman, Vincent Wong, Mark Farber, Tim Lahm

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Current evidence suggests that exercise training is beneficial in pulmonary arterial hypertension (PAH). Unfortunately, the standard supervised, hospital-based programs limit patient accessibility to this important intervention. Our proof-of-concept study aimed to provide insight into the usefulness of a prescribed walking regimen along with arginine supplementation to improve outcomes for patients with PAH. Twelve PAH patients (all women) in New York Heart Association (NYHA) functional class (FC) II (n = 7) or III (n = 5) and in stable condition for ≥ 3 months were enrolled. Patients performed home- and fitness-center- based walking at 65– 75% heart rate (HR) reserve for 45 min, six sessions/week for 12 weeks. Concomitant L-arginine supplementation (6000 mg/day) was provided to maximize beneficial endothelial training adaptations. Cardiopulmonary exercise testing, 6-min walk testing (6MWT), echocardiography, laboratory studies, and quality of life (QoL) survey (SF-36) were performed at baseline and 12 weeks. Eleven patients completed the study (72 session adherence rate = 96 ± 3%). Objective improvement was demonstrated by the 6MWT distance (increased by 40 ± 13 m, P = 0.01), VO2max (increased by 2 ± 0.7 mL/kg/min, P ¼ 0.02), time-to-VO2max (increased by 2.5 ± 0.6 min, P = 0.001), VO2 at anaerobic threshold (increased by 1.3 ± 0.5 mL/kg/min, P =0.04), HR recovery (reduced by 68 ± 23% in slope, P = 0.01), and SF-36 subscales of Physical Functioning and Energy/Fatigue (increased by 70 ± 34% and 74 ± 34%, respectively, P < 0.05). No adverse events occurred, and right ventricular function and brain natriuretic peptide levels remained stable, suggesting safety of the intervention. This proof-of-concept study indicates that a simple walking regimen with arginine supplementation is a safe and efficacious intervention for clinically stable PAH patients, with gains in objective function and QoL measures. Further investigation in a randomized controlled trial is warranted.

Original languageEnglish (US)
JournalPulmonary Circulation
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Pulmonary Hypertension
Walking
Arginine
Quality of Life
Heart Rate
Fitness Centers
Exercise
Anaerobic Threshold
Right Ventricular Function
Brain Natriuretic Peptide
Fatigue
Echocardiography
Randomized Controlled Trials
Safety

Keywords

  • Aerobic exercise
  • Cardiopulmonary rehabilitation
  • Exercise training
  • Home exercise program
  • PAH

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

A prescribed walking regimen plus arginine supplementation improves function and quality of life for patients with pulmonary arterial hypertension : A pilot study. / Brown, Mary Beth; Kempf, Attie; Collins, Catherine M.; Long, Gary M.; Owens, Matthew; Gupta, Shikha; Hellman, Yaron; Wong, Vincent; Farber, Mark; Lahm, Tim.

In: Pulmonary Circulation, Vol. 8, No. 1, 01.01.2018.

Research output: Contribution to journalArticle

Brown, Mary Beth ; Kempf, Attie ; Collins, Catherine M. ; Long, Gary M. ; Owens, Matthew ; Gupta, Shikha ; Hellman, Yaron ; Wong, Vincent ; Farber, Mark ; Lahm, Tim. / A prescribed walking regimen plus arginine supplementation improves function and quality of life for patients with pulmonary arterial hypertension : A pilot study. In: Pulmonary Circulation. 2018 ; Vol. 8, No. 1.
@article{b6d5d965f18e4bedb504f0be190a8221,
title = "A prescribed walking regimen plus arginine supplementation improves function and quality of life for patients with pulmonary arterial hypertension: A pilot study",
abstract = "Current evidence suggests that exercise training is beneficial in pulmonary arterial hypertension (PAH). Unfortunately, the standard supervised, hospital-based programs limit patient accessibility to this important intervention. Our proof-of-concept study aimed to provide insight into the usefulness of a prescribed walking regimen along with arginine supplementation to improve outcomes for patients with PAH. Twelve PAH patients (all women) in New York Heart Association (NYHA) functional class (FC) II (n = 7) or III (n = 5) and in stable condition for ≥ 3 months were enrolled. Patients performed home- and fitness-center- based walking at 65– 75{\%} heart rate (HR) reserve for 45 min, six sessions/week for 12 weeks. Concomitant L-arginine supplementation (6000 mg/day) was provided to maximize beneficial endothelial training adaptations. Cardiopulmonary exercise testing, 6-min walk testing (6MWT), echocardiography, laboratory studies, and quality of life (QoL) survey (SF-36) were performed at baseline and 12 weeks. Eleven patients completed the study (72 session adherence rate = 96 ± 3{\%}). Objective improvement was demonstrated by the 6MWT distance (increased by 40 ± 13 m, P = 0.01), VO2max (increased by 2 ± 0.7 mL/kg/min, P ¼ 0.02), time-to-VO2max (increased by 2.5 ± 0.6 min, P = 0.001), VO2 at anaerobic threshold (increased by 1.3 ± 0.5 mL/kg/min, P =0.04), HR recovery (reduced by 68 ± 23{\%} in slope, P = 0.01), and SF-36 subscales of Physical Functioning and Energy/Fatigue (increased by 70 ± 34{\%} and 74 ± 34{\%}, respectively, P < 0.05). No adverse events occurred, and right ventricular function and brain natriuretic peptide levels remained stable, suggesting safety of the intervention. This proof-of-concept study indicates that a simple walking regimen with arginine supplementation is a safe and efficacious intervention for clinically stable PAH patients, with gains in objective function and QoL measures. Further investigation in a randomized controlled trial is warranted.",
keywords = "Aerobic exercise, Cardiopulmonary rehabilitation, Exercise training, Home exercise program, PAH",
author = "Brown, {Mary Beth} and Attie Kempf and Collins, {Catherine M.} and Long, {Gary M.} and Matthew Owens and Shikha Gupta and Yaron Hellman and Vincent Wong and Mark Farber and Tim Lahm",
year = "2018",
month = "1",
day = "1",
doi = "10.1177/2045893217743966",
language = "English (US)",
volume = "8",
journal = "Pulmonary Circulation",
issn = "2045-8932",
publisher = "University of Chicago Press",
number = "1",

}

TY - JOUR

T1 - A prescribed walking regimen plus arginine supplementation improves function and quality of life for patients with pulmonary arterial hypertension

T2 - A pilot study

AU - Brown, Mary Beth

AU - Kempf, Attie

AU - Collins, Catherine M.

AU - Long, Gary M.

AU - Owens, Matthew

AU - Gupta, Shikha

AU - Hellman, Yaron

AU - Wong, Vincent

AU - Farber, Mark

AU - Lahm, Tim

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Current evidence suggests that exercise training is beneficial in pulmonary arterial hypertension (PAH). Unfortunately, the standard supervised, hospital-based programs limit patient accessibility to this important intervention. Our proof-of-concept study aimed to provide insight into the usefulness of a prescribed walking regimen along with arginine supplementation to improve outcomes for patients with PAH. Twelve PAH patients (all women) in New York Heart Association (NYHA) functional class (FC) II (n = 7) or III (n = 5) and in stable condition for ≥ 3 months were enrolled. Patients performed home- and fitness-center- based walking at 65– 75% heart rate (HR) reserve for 45 min, six sessions/week for 12 weeks. Concomitant L-arginine supplementation (6000 mg/day) was provided to maximize beneficial endothelial training adaptations. Cardiopulmonary exercise testing, 6-min walk testing (6MWT), echocardiography, laboratory studies, and quality of life (QoL) survey (SF-36) were performed at baseline and 12 weeks. Eleven patients completed the study (72 session adherence rate = 96 ± 3%). Objective improvement was demonstrated by the 6MWT distance (increased by 40 ± 13 m, P = 0.01), VO2max (increased by 2 ± 0.7 mL/kg/min, P ¼ 0.02), time-to-VO2max (increased by 2.5 ± 0.6 min, P = 0.001), VO2 at anaerobic threshold (increased by 1.3 ± 0.5 mL/kg/min, P =0.04), HR recovery (reduced by 68 ± 23% in slope, P = 0.01), and SF-36 subscales of Physical Functioning and Energy/Fatigue (increased by 70 ± 34% and 74 ± 34%, respectively, P < 0.05). No adverse events occurred, and right ventricular function and brain natriuretic peptide levels remained stable, suggesting safety of the intervention. This proof-of-concept study indicates that a simple walking regimen with arginine supplementation is a safe and efficacious intervention for clinically stable PAH patients, with gains in objective function and QoL measures. Further investigation in a randomized controlled trial is warranted.

AB - Current evidence suggests that exercise training is beneficial in pulmonary arterial hypertension (PAH). Unfortunately, the standard supervised, hospital-based programs limit patient accessibility to this important intervention. Our proof-of-concept study aimed to provide insight into the usefulness of a prescribed walking regimen along with arginine supplementation to improve outcomes for patients with PAH. Twelve PAH patients (all women) in New York Heart Association (NYHA) functional class (FC) II (n = 7) or III (n = 5) and in stable condition for ≥ 3 months were enrolled. Patients performed home- and fitness-center- based walking at 65– 75% heart rate (HR) reserve for 45 min, six sessions/week for 12 weeks. Concomitant L-arginine supplementation (6000 mg/day) was provided to maximize beneficial endothelial training adaptations. Cardiopulmonary exercise testing, 6-min walk testing (6MWT), echocardiography, laboratory studies, and quality of life (QoL) survey (SF-36) were performed at baseline and 12 weeks. Eleven patients completed the study (72 session adherence rate = 96 ± 3%). Objective improvement was demonstrated by the 6MWT distance (increased by 40 ± 13 m, P = 0.01), VO2max (increased by 2 ± 0.7 mL/kg/min, P ¼ 0.02), time-to-VO2max (increased by 2.5 ± 0.6 min, P = 0.001), VO2 at anaerobic threshold (increased by 1.3 ± 0.5 mL/kg/min, P =0.04), HR recovery (reduced by 68 ± 23% in slope, P = 0.01), and SF-36 subscales of Physical Functioning and Energy/Fatigue (increased by 70 ± 34% and 74 ± 34%, respectively, P < 0.05). No adverse events occurred, and right ventricular function and brain natriuretic peptide levels remained stable, suggesting safety of the intervention. This proof-of-concept study indicates that a simple walking regimen with arginine supplementation is a safe and efficacious intervention for clinically stable PAH patients, with gains in objective function and QoL measures. Further investigation in a randomized controlled trial is warranted.

KW - Aerobic exercise

KW - Cardiopulmonary rehabilitation

KW - Exercise training

KW - Home exercise program

KW - PAH

UR - http://www.scopus.com/inward/record.url?scp=85041423567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041423567&partnerID=8YFLogxK

U2 - 10.1177/2045893217743966

DO - 10.1177/2045893217743966

M3 - Article

AN - SCOPUS:85041423567

VL - 8

JO - Pulmonary Circulation

JF - Pulmonary Circulation

SN - 2045-8932

IS - 1

ER -